ImmunityBio Launches Subsidiary in Saudi Arabia for ANKTIVA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Should l Buy IBRX?
Source: Newsfilter
ImmunityBio's stock surged by 12% as it reached a 52-week high, reflecting positive investor sentiment.
The company has established a wholly owned subsidiary in Saudi Arabia to support the launch of ANKTIVA, having received a Registration Certificate from the Saudi FDA. This marks ImmunityBio's official entry into the Saudi market, addressing the rising demand for cancer treatments. Additionally, partnerships with Biopharma and Cigalah, two major pharmaceutical distributors in the region, are expected to enhance commercialization efforts and accelerate patient access to ANKTIVA.
This strategic move positions ImmunityBio favorably in the MENA region, potentially leading to increased market share and revenue growth as the company expands its footprint in the oncology sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.780
Low
5.00
Averages
7.33
High
9.00
Current: 9.780
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio's 2025 Outlook Shows Positive Trends
- EBIT Loss Narrowing: ImmunityBio anticipates its EBIT loss will narrow to $256.03 million in 2025 from $344.18 million last year, indicating significant improvement in its commercialization efforts and boosting investor confidence.
- Anktiva Commercialization Success: The projected net product revenue for Anktiva in 2025 is $113 million, a staggering 700% increase from the previous year, which not only enhances overall company revenue but also signals strong market demand and potential for long-term growth.
- Clinical Trial Progress: The Phase 2 Quilt 2.005 trial results show that 85% of patients receiving Anktiva combined with BCG remained cancer-free after six months, significantly outperforming the 57% rate for those treated with BCG alone, laying a solid foundation for future biologics license application.
- Founder Media Promotion: Founder Patrick Soon-Shiong amplified the scientific significance of Anktiva through various media appearances, highlighting the potential of IL-15 to support additional indications, which has increased market attention and expectations for the product.
See More
Nvidia Reports Strong Earnings but Shares Decline
- Earnings Beat: Nvidia's fourth-quarter results surpassed revenue and profit expectations, indicating sustained demand for its AI compute platforms; however, the stock price sharply declined, reflecting investor skepticism about the sustainability of high expectations.
- Cautious Market Reaction: Despite Nvidia's strong performance, Wall Street's muted response highlights a shift in focus from headline earnings to deeper concerns regarding long-term growth, capital returns, and competitive dynamics in the AI sector.
- Increased Competitive Pressure: As rival AI hardware efforts gain traction, investors are increasingly concerned about future spending patterns and competition from alternative AI chip designs, which has pressured broader technology stocks and underscored the fragility of the AI-led market rally.
- Significant Industry Impact: Nvidia's pullback not only affected its own stock but also weighed heavily on the semiconductor sector, contributing to sluggish performance among major tech benchmarks late in the week, indicating a waning confidence in AI-related stocks.
See More
ImmunityBio to Host Conference Call on March 3, 2026
- Conference Call Details: ImmunityBio will host a conference call on March 3, 2026, at 1:30 PM PT to provide a business update and review 2025 financial results, reflecting the company's commitment to transparency and investor communication.
- Clinical Trial Progress: The call will cover advancements in the company's clinical trial pipeline, indicating ImmunityBio's ongoing innovation and R&D efforts in immunotherapies for cancer and infectious diseases, which may impact future market competitiveness.
- Investor Access: Investors can join the call via the company's Investor Relations website or by dialing specified numbers, emphasizing the company's focus on enhancing investor experience by encouraging timely participation.
- Replay Availability: A replay of the call will be available on the Investor Relations website for at least 90 days post-event, increasing information accessibility and transparency for stakeholders.
See More
ImmunityBio Sparks Retail Trader Speculation Ahead of Key Media Appearances
- Media Exposure Effect: ImmunityBio's founder Soon-Shiong is set to appear on Fox News and NewsNation on Friday, triggering retail traders' speculation about potential policy, funding, or regulatory developments, leading to a more than 380% surge in IBRX stock on Thursday.
- Clinical Trial Progress: ImmunityBio completed enrollment of 366 patients ahead of schedule in its key Phase 2 trial, showing that 85% of patients receiving Anktiva with BCG remained cancer-free after six months, significantly outperforming the 57% of those treated with BCG alone, with a biologics license application expected by Q4 2026.
- Investor Sentiment Surge: On Stocktwits, retail sentiment for IBRX is described as 'extremely bullish' with high message volume, as investors speculate that Soon-Shiong's media appearances could signal major announcements, potentially linked to non-dilutive funding from Saudi Arabia.
- Critique of Big Pharma Influence: Soon-Shiong criticized the reliance on chemotherapy in modern cancer care during his appearance on The Daily Show, arguing that this model has been shaped by decades of collaboration with big pharmaceutical companies, highlighting the need for a shift in cancer treatment strategies to reduce dependency on chemotherapy.
See More
ImmunityBio Completes Key Clinical Trial Enrollment
- Clinical Trial Progress: ImmunityBio has completed enrollment of 366 patients ahead of schedule in its pivotal randomized trial QUILT 2.005, evaluating the efficacy of Anktiva plus BCG against BCG alone for treating non-muscle invasive bladder cancer, with 85% of patients maintaining a complete response at six months, significantly higher than the 57% in the BCG-only group.
- Sales Surge: The company reported a remarkable 750% year-over-year increase in Anktiva sales, rising from $7.56 million to $38.29 million, surpassing the consensus estimate of $37.02 million, indicating strong market demand across 33 countries.
- FDA Application Plans: Based on the promising trial results, ImmunityBio anticipates submitting a biologics license application (BLA) to the FDA by the fourth quarter of 2026, which will lay the groundwork for future market expansion.
- Market Performance Analysis: ImmunityBio's stock rose 3.97% to $9.91 during Thursday's premarket trading, currently trading 2.41% above its 20-day simple moving average, indicating short-term strength, with analysts unanimously rating it as a
See More
ImmunityBio's ANKTIVA Trial Enrollment Completed Early
- Early Trial Enrollment: ImmunityBio completed enrollment of 366 patients in its Phase 2 ANKTIVA trial ahead of schedule, indicating significant progress in the treatment of non-muscle invasive bladder cancer, which may accelerate subsequent clinical development.
- FDA Interim Analysis Results: An interim analysis requested by the FDA revealed that 84% of patients receiving the ANKTIVA and BCG combination maintained a complete response at nine months, compared to only 52% for those on BCG alone, demonstrating a significant efficacy improvement.
- No Major Safety Concerns: The interim analysis indicated no major safety issues with the ANKTIVA and BCG combination treatment, providing confidence for future clinical applications and potentially attracting more investor interest.
- Future Application Plans: ImmunityBio plans to submit a biologics license application by the fourth quarter of 2026, which, if approved, could provide a new revenue stream and further solidify its market position in the biopharmaceutical sector.
See More
ImmunityBio's 2025 Outlook Shows Positive Trends
- EBIT Loss Narrowing: ImmunityBio anticipates its EBIT loss will narrow to $256.03 million in 2025 from $344.18 million last year, indicating significant improvement in its commercialization efforts and boosting investor confidence.
- Anktiva Commercialization Success: The projected net product revenue for Anktiva in 2025 is $113 million, a staggering 700% increase from the previous year, which not only enhances overall company revenue but also signals strong market demand and potential for long-term growth.
- Clinical Trial Progress: The Phase 2 Quilt 2.005 trial results show that 85% of patients receiving Anktiva combined with BCG remained cancer-free after six months, significantly outperforming the 57% rate for those treated with BCG alone, laying a solid foundation for future biologics license application.
- Founder Media Promotion: Founder Patrick Soon-Shiong amplified the scientific significance of Anktiva through various media appearances, highlighting the potential of IL-15 to support additional indications, which has increased market attention and expectations for the product.
See More
Nvidia Reports Strong Earnings but Shares Decline
- Earnings Beat: Nvidia's fourth-quarter results surpassed revenue and profit expectations, indicating sustained demand for its AI compute platforms; however, the stock price sharply declined, reflecting investor skepticism about the sustainability of high expectations.
- Cautious Market Reaction: Despite Nvidia's strong performance, Wall Street's muted response highlights a shift in focus from headline earnings to deeper concerns regarding long-term growth, capital returns, and competitive dynamics in the AI sector.
- Increased Competitive Pressure: As rival AI hardware efforts gain traction, investors are increasingly concerned about future spending patterns and competition from alternative AI chip designs, which has pressured broader technology stocks and underscored the fragility of the AI-led market rally.
- Significant Industry Impact: Nvidia's pullback not only affected its own stock but also weighed heavily on the semiconductor sector, contributing to sluggish performance among major tech benchmarks late in the week, indicating a waning confidence in AI-related stocks.
See More
ImmunityBio to Host Conference Call on March 3, 2026
- Conference Call Details: ImmunityBio will host a conference call on March 3, 2026, at 1:30 PM PT to provide a business update and review 2025 financial results, reflecting the company's commitment to transparency and investor communication.
- Clinical Trial Progress: The call will cover advancements in the company's clinical trial pipeline, indicating ImmunityBio's ongoing innovation and R&D efforts in immunotherapies for cancer and infectious diseases, which may impact future market competitiveness.
- Investor Access: Investors can join the call via the company's Investor Relations website or by dialing specified numbers, emphasizing the company's focus on enhancing investor experience by encouraging timely participation.
- Replay Availability: A replay of the call will be available on the Investor Relations website for at least 90 days post-event, increasing information accessibility and transparency for stakeholders.
See More
ImmunityBio Sparks Retail Trader Speculation Ahead of Key Media Appearances
- Media Exposure Effect: ImmunityBio's founder Soon-Shiong is set to appear on Fox News and NewsNation on Friday, triggering retail traders' speculation about potential policy, funding, or regulatory developments, leading to a more than 380% surge in IBRX stock on Thursday.
- Clinical Trial Progress: ImmunityBio completed enrollment of 366 patients ahead of schedule in its key Phase 2 trial, showing that 85% of patients receiving Anktiva with BCG remained cancer-free after six months, significantly outperforming the 57% of those treated with BCG alone, with a biologics license application expected by Q4 2026.
- Investor Sentiment Surge: On Stocktwits, retail sentiment for IBRX is described as 'extremely bullish' with high message volume, as investors speculate that Soon-Shiong's media appearances could signal major announcements, potentially linked to non-dilutive funding from Saudi Arabia.
- Critique of Big Pharma Influence: Soon-Shiong criticized the reliance on chemotherapy in modern cancer care during his appearance on The Daily Show, arguing that this model has been shaped by decades of collaboration with big pharmaceutical companies, highlighting the need for a shift in cancer treatment strategies to reduce dependency on chemotherapy.
See More
ImmunityBio Completes Key Clinical Trial Enrollment
- Clinical Trial Progress: ImmunityBio has completed enrollment of 366 patients ahead of schedule in its pivotal randomized trial QUILT 2.005, evaluating the efficacy of Anktiva plus BCG against BCG alone for treating non-muscle invasive bladder cancer, with 85% of patients maintaining a complete response at six months, significantly higher than the 57% in the BCG-only group.
- Sales Surge: The company reported a remarkable 750% year-over-year increase in Anktiva sales, rising from $7.56 million to $38.29 million, surpassing the consensus estimate of $37.02 million, indicating strong market demand across 33 countries.
- FDA Application Plans: Based on the promising trial results, ImmunityBio anticipates submitting a biologics license application (BLA) to the FDA by the fourth quarter of 2026, which will lay the groundwork for future market expansion.
- Market Performance Analysis: ImmunityBio's stock rose 3.97% to $9.91 during Thursday's premarket trading, currently trading 2.41% above its 20-day simple moving average, indicating short-term strength, with analysts unanimously rating it as a
See More
ImmunityBio's ANKTIVA Trial Enrollment Completed Early
- Early Trial Enrollment: ImmunityBio completed enrollment of 366 patients in its Phase 2 ANKTIVA trial ahead of schedule, indicating significant progress in the treatment of non-muscle invasive bladder cancer, which may accelerate subsequent clinical development.
- FDA Interim Analysis Results: An interim analysis requested by the FDA revealed that 84% of patients receiving the ANKTIVA and BCG combination maintained a complete response at nine months, compared to only 52% for those on BCG alone, demonstrating a significant efficacy improvement.
- No Major Safety Concerns: The interim analysis indicated no major safety issues with the ANKTIVA and BCG combination treatment, providing confidence for future clinical applications and potentially attracting more investor interest.
- Future Application Plans: ImmunityBio plans to submit a biologics license application by the fourth quarter of 2026, which, if approved, could provide a new revenue stream and further solidify its market position in the biopharmaceutical sector.
See More
